ARTICLE | Company News
Amylin NDA accepted for review
January 25, 2001 8:00 AM UTC
The FDA accepted for review AMLN's NDA for Symlin pramlintide synthetic analog of amylin hormone as an adjunctive therapy to insulin to treat patients with Type I or Type II diabetes taking insulin. A...